argenx NV ADR (ARGX) — Technical state
As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 63 out of 100 (momentum 79 · quality 74 · valuation 27), as of 2026-11-11.
- Signal: Uptrend stack intact — Trades +4.7% vs the 50-day and +13.2% vs the 200-day average, 9.4% below the 52-week high and +46.8% off the 52-week low. Computed from daily closes. (as of 2026-11-10)
- Trend: argenx NV ADR trades 4.7% above its 50-day and 13.2% above its 200-day moving average. (as of 2026-11-10)
argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the ARGX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades +4.7% vs the 50-day and +13.2% vs the 200-day average, 9.4% below the 52-week high and +46.8% off the 52-week low. Computed from daily closes.
The moving-average stack
- vs 20-day+9.7%
- vs 50-day+4.7%
- vs 200-day+13.2%
- 52-week band9.4% off the high · +46.8% off the low
- Streak3 consecutive up sessions
- 50-day crossprice crossed up through the 50-day 1 sessions ago
- Stochastic%K 96.1 · %D 85.7
Continue: the ARGX chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-10
Quick answers
What is the current Closelooknet signal on ARGX?
Uptrend stack intact — Trades +4.7% vs the 50-day and +13.2% vs the 200-day average, 9.4% below the 52-week high and +46.8% off the 52-week low. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is ARGX above its 50-day and 200-day moving averages?
As of 2026-11-10, argenx NV ADR trades +4.7% above its 50-day and +13.2% above its 200-day average, with the 20-day +9.7% away.
How far is ARGX from its 52-week high?
9.4% below the 52-week high and 46.8% above the 52-week low, as of 2026-11-10.
Mentioned on Closelooknet
Where ARGX appears in the diary — 1 piece, newest first. Every link is our own writing.
Go deeper
Dailies
- A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000
Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG…
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeOne Medicines AGindustry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- RIGL Rigel Pharmaceuticals Incindustry
- REPL Replimune Group Incindustry
- KOD Kodiak Sciences Incindustry
- XNCR Xencor Incindustry
- VCEL Vericel Corp Ordindustry
- VRDN Viridian Therapeutics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- MRNA Moderna Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- ORKA Oruka Therapeutics, Inc.industry
- ADMA ADMA Biologics Incindustry
- PHARM.AS Pharming Group NVindustry
- MEDCL.PA Medincell SAindustry
- DNA Ginkgo Bioworks Holdingsindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry